A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Phase 3 Recruiting 375 enrolled Zhejiang Wenda Pharma Technology LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Timeline

Start: 2026-03-18
Primary completion: 2026-11-30
Completion: 2027-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WD-890	Unknown	—	Oral

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Summary

Timeline

Drugs

Indications